ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions
View by Date

Sunday, November 7, 2021

8:30AM-10:30AM
Abstract Number: 0626
Does Higher Quality of Care in SLE Translate to Better Patient Outcomes?
Measures & Measurement of Healthcare Quality Poster (0623–0659)
8:30AM-10:30AM
Abstract Number: 0902
Does Imaging of the Sacroiliac Joint and Spine Differ in Patients Presenting with Undiagnosed Back Pain and Psoriasis, Acute Anterior Uveitis, and Colitis: An Inception Cohort Study
Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster II: Imaging in Spondyloarthritis (0897–0907)
8:30AM-10:30AM
Abstract Number: 0864
Does Obesity Affect Disease Activity Outcomes in Systemic Lupus Erythematosus?
SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)
8:30AM-10:30AM
Abstract Number: 0672
Does Obesity Affect Gout Risk Differently Among Genetically Predisposed Individuals?: Sex-Specific Prospective Cohort Study Findings over >32 Years
Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)
8:30AM-10:30AM
Abstract Number: 0724
Dose (Exposure) Efficacy Response of Tanezumab Following Intravenous and Subcutaneous Administration Across Phase 2 and Phase 3 Studies in Patients with Osteoarthritis of Hip and Knee
Osteoarthritis – Clinical Poster II (0723–0738)
8:30AM-10:30AM
Abstract Number: 0911
Drug Retention of Tumor Necrosis Factors and IL-17 Inhibitors in Axial Spondyloarthritis: A Multi-Center Comparative Analysis
Spondyloarthritis Including PsA – Treatment Poster I: Axial Spondyloarthritis (0908–0939)
8:30AM-10:30AM
Abstract Number: 0516
Dual Fibroblast Transdifferentiation Mediated by Type I Interferon: Application to Anti-Ro Mediated Congenital Heart Block
Cytokines & Cell Trafficking Poster (0508–0516)
8:30AM-10:30AM
Abstract Number: PP04
Dual Roles: Thriving with SLE as a Medical Student
Patient Perspectives Poster (PP01–PP09)
8:30AM-10:30AM
Abstract Number: 0530
Dysregulation of IGFI/IGF1R Pathway and IGF1R+3179A/G Polymorphism in Pathogenesis of Sjögren’s Syndrome
Genetics, Genomics & Proteomics Poster (0517–0533)
8:30AM-10:30AM
Abstract Number: 0931
Early Improvement in Disease Activity Indices Predicts Achievement of Long-term Clinical Remissions, ASDAS Inactive Disease and Low BASDAI with Normal CRP, During TNF-α-inhibitor Therapy in Patients with Ankylosing Spondylitis
Spondyloarthritis Including PsA – Treatment Poster I: Axial Spondyloarthritis (0908–0939)
8:30AM-10:30AM
Abstract Number: 0801
Early Remission at 6 Months as a Predictor of Longterm Remission in New Onset Rheumatoid Arthritis
RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)
8:30AM-10:30AM
Abstract Number: 0669
Early-Onset Gout (EOG) Patients Are an Important and Recalcitrant Phenotype Warranting Further Investigation: A Systematic Review
Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)
8:30AM-10:30AM
Abstract Number: 0881
Economic Evaluation of Neuropsychiatric (NP) Lupus in an International Inception Cohort Using a Multistate Model Approach
SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)
8:30AM-10:30AM
Abstract Number: 0858
Effect of COVID Infection and COVID Vaccination on SLE Activity, Including Antiphospholipid Antibodies
SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)
8:30AM-10:30AM
Abstract Number: 0750
Effect of Deucravacitinib on the Psoriatic Arthritis Impact of Disease Questionnaires 12 and 9: Analysis of a Phase 2 Study of Active Psoriatic Arthritis
Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)
  • «Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 34
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology